To understand short-term prevention (STP) of migraine from the perspective of healthcare providers (HCPs) and rimegepant patient STP users.

STP is a time-limited treatment before migraine onset for patients with known triggers/situations where avoiding migraine is preferred. Rimegepant, indicated for acute and preventive migraine treatment, potentially provides patients with a flexible option for STP.

Among 277 HCPs, 86% discussed STP with their patients with migraine. Over 90% of HCPs agreed that STP should be discussed with patients who have reliable triggers or specific situations when migraine avoidance is preferred. HCPs considered efficacy and side effects/tolerability as the most important treatment considerations when discussing STP with patients. HCPs mostly prescribed gepants for STP, with rimegepant as the preferred gepant. Among 152 STP users, 88% were informed about the use of rimegepant for STP by their prescriber physician and 61% received their first rimegepant prescription from a primary care provider. Patients had taken rimegepant for STP once (36%), daily (38%), or every other day (QOD, 42%). Patients last used rimegepant as STP for 1 (24%), 2-3 (52%), 4-10 (16%), or >10 (9%) days. Most patients were satisfied/extremely satisfied with rimegepant for STP after taking it once (80%), daily (77%), or QOD (77%).

HCPs support discussing STP with patients who have predictable triggers/specific situations to prevent a migraine attack. Findings suggest that both HCPs and patients perceive the potential benefits of STP and flexible use of rimegepant for STP.